The company’s clinical lead, CB-103, has advanced to phase 2 in oncology, followed by a rich R&D pipeline of novel gene transcription factor inhibitors targeting oncology, autoimmune and ...
“The initiation of the Phase 1b trial in subjects with moderate-to-severe plaque psoriasis represents a major step forward in advancing our novel and highly selective oral BET ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback